Background
Cardiopulmonary bypass (CPB) results in an inflammatory response propagated by numerous pathways, including coagulation 1 . Aprotinin reduces the use of blood products during cardiac surgery 2, 3 . 'High dose' aprotinin regimes (resulting in kallikrein inhibition) reduce allogeneic blood requirements more than 'low dose' regimes 4, 5 .
DX-88 (Dyax Corp, Cambridge, MA), is a novel kallikrein inhibitor, undergoing trials as a drug to reduce transfusion requirements in cardiac surgery 67 . The Thrombelastograph (TEG, Haemoscope) is a global monitor of whole blood coagulation 8 , used to guide blood component therapy in cardiac surgery 9, 10 . Therefore, this work aims to investigate the effect of DX-88, in vitro, on blood samples taken from patients undergoing CPB using the TEG, and assess the effect of changes in contact factor proteins.
Hypothesis
DX-88 will have an in vitro effect on thrombelastography, caused by kallikrein inhibition. During CPB, DX-88 will reduce fibrinolysis.
Research Questions
1. What is the in vitro effect of DX-88 on whole blood coagulation in CPB? 2. How does contact activation and haemodilution during CPB explain this effect?
Methods
Twenty-five patients undergoing elective cardiac surgery on CPB were recruited following informed consent, and institutional ethical approval. Blood was sampled via a CVP line into citrated tubes, after induction of anaesthesia and during CPB (at rewarming).
Kaolin activated thrombelastography was performed after recalcification, using heparinase cups; DX-88 was added in doses of 5, 10 and 20 µg/ml and compared to a buffer control. TEG analysis of the citrated samples was performed at least 30 minutes after blood sampling 11, 12 .
Plasma was stored at -70 o C for assays of contact factor proteins, heparin and IgM concentration (as a measure of haemodilution 13 ). Heparin was measured by anti-Xa assay (Dade Behring), amidolytic assays were performed for prekallikrein (PKK), kallikrein-like activity (KKA), factor XII (FXII), factor XIIA-like activity (FXIIA) and factor XI (FXI) (Unicorn Diagnostics). C1-inhibitor (C1-INH) and IgM antigen were measured by ELISA.
Paired data (pre and post CPB) were analysed using the Wilcoxon signed ranks test.
Results
Patients were separated according to intra-operative aprotinin administration: fifteen of the twenty-five patients received aprotinin (after the first blood sample had been taken).
DX-88 caused a dose dependent increase in TEG r time, which was greater during CPB than before CPB (Table 1) . This effect was enhanced in those patients receiving aprotinin. In addition, at both time points DX-88 caused an increase in TEG k time, and a reduction in alpha angle. None of the patients studied had hyperfibrinolysis during CPB (defined by one group as TEG Ly30 > 7.5 % 14 ), therefore it was not possible to demonstrate an antifibrinolytic effect of DX-88. 
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Conclusions
These results support our hypothesis that DX-88 has an in vitro effect on whole blood coagulation, as demonstrated by thrombelastography in patients undergoing CPB. The major effect on the TEG was prolongation of the r time. A similar effect has previously been reported for aprotinin 15 ; this is unsurprising as both drugs inhibit kallikrein and therefore the intrinsic pathway of coagulation. However, aprotinin only prolongs TEG r time when
Results of plasma assays are shown in Table 2 . Plasma heparin levels, measured during CPB, show considerable variability (2.2-7.3 IU/ml) amongst the patients studied. This may reflect differences in sampling time, or variation in heparin dose. Heparin was detected before CPB, presumably due to heparin flush in the CVP lines. Unsurprisingly, plasma IgM concentration decreases during CPB reflecting haemodilution. CPB was associated with contact activation, demonstrated by decreased PKK and factor XII levels, and increase factor XIIa like activity.
celite or kaolin are used as activators, but not when tissue factor is the activator 16 . In this study, kaolin activated TEG was used to investigate DX-88 in CPB; further work is needed to investigate whether similar results are seen with tissue factor activated TEG. Healthy volunteer studies suggest that DX-88 does not affect the tissue factor activated TEG 6 .
During CPB, there is a dramatic dose dependent increase in r time on addition of DX-88; the effect is much greater in patients receiving aprotinin. The changes would be explained by decreased function of contact factor proteins, either by depletion during CPB or by haemodilution.
This study demonstrates that CPB is associated with contact factor activation, as previously shown by another group 17 . The contact system modulates coagulation, fibrinolysis, and inflammation 18 , however there is debate regarding the significance of contact activation in CPB 19, 20 .
Measurements of plasma IgM concentrations suggest haemodilution during CPB. Contact factor results may require correction for haemodilution before further interpretation of clotting factor activity.
Relevance to Intensive Care
Drugs used to reduce blood product transfusion may have a direct effect on measures of coagulation, such as the TEG. If the clinician is unaware of this effect, the TEG may be incorrectly interpreted when used to guide blood product therapy.
We demonstrated contact factor activation during CPB, reflecting an inflammatory response 1 . Critical illness may also result in an inflammatory response; contact activation occurs in intensive care patients 21, 22 . However, an observational study of twelve intensive care patients undergoing haemofiltration failed to show contact activation 23 . Contact activation may therefore be more related to an inflammatory response than exposure of blood to a 'foreign' surface of an extracorporeal circulation. This is supported by a revised hypothesis for activation of the plasma kallikrein / kinin system, suggesting a cellular mechanism, rather than autoactivation of FXII on a negatively charged surface 24 .
We found small amounts of heparin in blood sampled from central venous lines, before CPB. Traces of heparin in blood samples from arterial or CVP lines may influence coagulation studies. There is conflicting evidence as to the clinical importance of this effect 25, 26 .
